Zirconium-89 girentuximab
Zirconium-89 girentuximab is Telix's PET scan that tells whether a kidney mass is clear cell renal cell carcinoma without a biopsy; the phase 3 ZIRCON trial met its endpoints in 2023 and the product is under regulatory review.
Overview
Telix Pharmaceuticals' TLX250-CDx labels the anti-CAIX antibody girentuximab with zirconium-89. In the ZIRCON phase 3 trial of 300 patients with indeterminate renal masses, the scan identified clear cell renal cell carcinoma with high sensitivity and specificity against surgical histology. Telix filed with the FDA, which issued a refusal-to-file letter in 2024 over manufacturing information, and a resubmission followed. A further phase 3 trial is registered.
- Detector ring
- CD8 minibody (T cells)
- 511 keV photon pair
1.Zirconium-89 girentuximab binds its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Zirconium-89 girentuximab" OR ABSTRACT:"Zirconium-89 girentuximab" OR TITLE:"TLX250-CDx" OR ABSTRACT:"TLX250-CDx" OR TITLE:"89Zr-DFO-girentuximab" OR ABSTRACT:"89Zr-DFO-girentuximab" OR TITLE:"Zircaix" OR ABSTRACT:"Zircaix") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Zirconium-89 girentuximab, not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialPhase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Shares CAIX (carbonic anhydrase IX), Renal cell carcinoma and the tag pipeline.
- TechnologyCAIX PET (89Zr-girentuximab)
Shares ZIRCON, ZIRCON: [89Zr]Zr-girentuximab PET-CT for detecting clear-cell renal cell carcinoma, CAIX imaging of the indeterminate renal mass, CAIX (carbonic anhydrase IX).
- TrialAn Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Shares Zirconium-89 and the tag pipeline.
- TrialA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Shares Renal cell carcinoma and the tag pipeline.
- TrialTest-retest Evaluation of [18F]F-AraG PET
Shares PET (positron emission tomography) and the tag pipeline.
- TrialPSMA-PET to Guide Prostatectomy
Shares PET (positron emission tomography) and the tag pipeline.
- TrialA Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors
Shares PET (positron emission tomography) and the tag pipeline.
- TrialInvestigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
Shares PET (positron emission tomography) and the tag pipeline.